# US 2004/0071633 A1 · Method for determining efficacy of reverse cholesterol transport enhancing agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0071633 A1
- Document ID: US20040071633A1
- Status: Published application
- Kind: A1
- Application number: 10/467,760
- Filed: 2003-08-13
- Published: 2004-04-15
- Earliest claimed: 2003-08-13
- Inventors: Samuel D. Wright; Tian-Quan Cai
- Web page: https://patentgrep.com/patent/US20040071633A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention provides a method for screening and/or determining the efficacy of known or potential reverse cholesterol transport-enhancing compounds in mammals that avoids the need for measuring cellular protein or mRNA levels and instead employs measurements of CD14 levels in blood.

## Claims

### Claim 1

A method for evaluating the efficacy of a reverse cholesterol transport-enhancing test agent in a mammal comprising
measuring the level of CD14 protein present in a standard sample of the mammal's blood to obtain one CD14 protein measurement;
measuring the level of CD14 protein present in a sample of the mammal's blood after administration of the test agent to obtain a second CD14 protein measurement; and
comparing the two CD14 protein measurements to determine if the measurement obtained after test agent administration is greater than the measurement obtained from the standard blood sample;
and wherein the CD14 protein is selected from sCD14 and mCD14 and is the same for both measurements.

### Claim 2 (depends on 1)

The method of claim 1 wherein the test agent is a potential RCT-enhancing agent.

### Claim 3 (depends on 1)

The method of claim 1 wherein the test agent is a known RCT-enhancing agent.

### Claim 4 (depends on 1)

The method of claim 1 wherein the standard blood sample is a sample of the mammal's blood absent administration of the test agent.

### Claim 5 (depends on 1)

The method of claim 1 wherein the standard blood sample is a sample of the mammal's blood after administration of a known RCT-enhancing agent.

### Claim 6

A method for determining relative efficacy for a reverse cholesterol transport-enhancing test agent in a mammal comprising:
measuring the level of CD14 protein present in a sample of the mammal's blood after administration of a standard RCT-enhancing agent to obtain one CD14 protein measurement;
measuring the level of CD14 protein present in a sample of the mammal's blood after administration of the test agent to obtain a second CD14 protein measurement; and
comparing the two CD14 protein measurements to determine the relative efficacy of the test agent as compared to that of the standard RCT-enhancing agent;
and wherein the CD14 protein is selected from sCD14 and mCD14 and is the same for both measurements.

### Claim 7 (depends on 6)

The method of claim 6 wherein the test agent is a potential RCT-enhancing agent.

### Claim 8 (depends on 6)

The method of claim 6 wherein the test agent is a known RCT-enhancing agent.

### Claim 9 (depends on 1)

The method of claim 1 wherein the test agent is an LXR ligand.

### Claim 10 (depends on 1)

The method of claim 1 wherein the test agent is a PPAR agonist.

### Claim 11 (depends on 1)

The method of claim 1 wherein the test agent is an HMG-CoA reductase inhibitor.

### Claim 12 (depends on 1)

The method of claim 1 wherein the test agent is a fish oil.

### Claim 13 (depends on 1)

The method of claim 1 wherein the test agent is an alcohol.

### Claim 14 (depends on 1)

The method of claim 1 wherein the test agent is a vitamin.

### Claim 15 (depends on 14)

The method of claim 14 wherein the test agent is niacin, niacinamide or an analog thereof.

### Claim 16 (depends on 1)

The method of claim 1 wherein the test agent is an ACAT inhibitor.

### Claim 17 (depends on 1)

The method of claim 1 wherein the test agent is a weight loss drug.

### Claim 18 (depends on 1)

The method of claim 1 wherein the test agent is a known or potential physical inducer of RCT enhancement.

### Claim 19 (depends on 1)

The method of claim 1 wherein the test agent is a known or potential behavioral inducer of RCT enhancement.

### Claim 20 (depends on 1)

The method of claim 1 wherein the mammal is a human.
